20 articles
Singapore researchers find calcium alpha-ketoglutarate repairs brain cell communication and restores early memory abilities in Alzheimer's models.
Japanese scientists engineered hybrid vitamin K molecules that are 3x more potent at regrowing neurons, potentially transforming Alzheimer's treatment.
A new joint venture completes a key manufacturing step for a cell therapy designed to restore α-Klotho, a protein linked to aging and disease.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
An oral iron-targeting drug significantly slowed Multiple System Atrophy progression in a Phase 2 trial, with Phase 3 planning underway.
A new compound stops a damaging protein from crippling brain cell energy factories, slowing Alzheimer's progression and extending lifespan in mice.
Maze Therapeutics' MZE829 reduced kidney damage markers by over 35% in patients with APOL1-mediated kidney disease in Phase 2 trials.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
A large study confirms current CKD diagnostic thresholds hold up under gold-standard kidney testing, while revealing which biomarker combo predicts risk best.
JCR Pharmaceuticals shows its JUST-AAV platform can cross the blood-brain barrier, extending survival in neurological disease mouse models.
Cyclarity's UDP-003 passed its first human trial with zero serious side effects, successfully flushing toxic 7-ketocholesterol through urine.
A placebo-controlled trial found daily MK-7 supplementation modestly reduced coronary artery calcification progression over two years.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
Salk Institute researchers found methionine supplementation dramatically improved survival in infected mice by enhancing kidney filtration of inflammatory molecules.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
A new wave of biotechs is targeting aging as a root cause, using encapsulated cells and gene therapy to restore lost proteins and reverse decline.
Non-obese MASLD patients face 3x higher Alzheimer's mortality risk, plus Vitamin E shows liver benefits in new gastroenterology roundup.
A modified B12 molecule delivers nitric oxide directly to glioblastoma tumors and boosts existing treatments in animal and lab studies.
A new GLP-1 therapy engineered to cross the blood-brain barrier enters Phase II trials, targeting cognitive decline in Parkinson's and Alzheimer's.
Johns Hopkins researchers find that a protein producing 'rotten egg' gas in tiny amounts may protect memory and prevent brain damage.
